Cellipont Bioservices
Aaron Hutchinson has a diverse work experience in various industries. Aaron is currently working as a Program Manager at Cellipont Bioservices since November 2022. Prior to this, they worked at PCI Pharma Services as a Clinical Project Manager from May 2020 to December 2022, and as an Associate Clinical Project Manager from October 2019 to July 2020. Before joining PCI Pharma Services, Aaron worked as a Research Associate at Smith & Nephew for a brief period in June 2019. Aaron also gained experience at Osiris Therapeutics, where they served as a Research Associate from September 2018 to June 2019, and as a Manufacturing Technician from November 2016 to September 2018. In addition to their pharmaceutical and research roles, Aaron worked as a Bartender at T.G.I. Fridays from May 2014 to August 2016, where they were responsible for providing excellent customer service and training staff members. Earlier in their career, they served as a Research Assistant at the Penn State University Musculoskeletal Regenerative Engineering Lab from August 2013 to December 2013.
Aaron Hutchinson attended Penn State University from 2009 to 2014, where they obtained a Bachelor's Degree in Biology, General. In terms of additional certifications, they completed the following courses: "Learning Python" from LinkedIn in November 2021, "SOLIDWORKS 2019 Essential Training" from LinkedIn in September 2019, "Learning C#" from LinkedIn in August 2019, and "Programming Foundations: Fundamentals (2011)" from LinkedIn in August 2019.
Cellipont Bioservices
Cellipont Bioservices is a cell therapy CDMO with more than 15 years’ experience in the development and small-to-large batch manufacturing of cell therapies. Our leaders have played an instrumental role in shaping cell therapy development and manufacturing methods and technologies, and our technically-strong team has been recognized by customers and technology partners for its ability to productively grow challenging cells. Cellipont is driven to help our clients to expand patient access to life-changing medicines through best-in-class development, analytical and manufacturing capabilities. We are a small company with a culture that is extremely responsive and customer-centric. Despite our size, Cellipont Bioservices has very deep technical experience, including 18,000+ tissue samples and more than 900 primary cell cultures. With decades of experience at advanced therapy service companies large and small, our leadership team is guiding Cellipont’s growth with deep knowledge of what it takes succeed in this space. Cellipont Bioservices facilities and quality systems are GMP-compliant and we hold a California Food & Drug Branch manufacturing license. We have extensive experience in multiple product areas, including CAR-T, iNK, dendritic cell, & other novel cell therapy approaches. OUR NAME: By combining “cell” with the latin root for bridge (pont), the name Cellipont Bioservices reflects several dimensions of what we are all about: we bridge our innovator clients with patients; we bridge technical excellence and personal service; and for our team, we bridge personal passion with professional vocation. As we finalize our corporate rebranding, we look forward to launching a new website in the coming weeks to better share our vision with you.